Rachael F Grace1, Jennifer Cohen2, Shayna Egan3,4, Ted Wells3,4, Brooke Witherspoon3,4, Aisling Ryan3,4, Sam S Salek5,6, Susan Bodie7, Robert J Klaassen8. 1. Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts. 2. Patient Advocate, Wrentham, Massachusetts. 3. Endpoint Outcomes, Boston, Massachusetts. 4. Endpoint Outcomes, Long Beach, California. 5. School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK. 6. Institute for Medicines Development, Cardiff, UK. 7. Agios Pharmaceuticals, Inc., Cambridge, Massachusetts. 8. Division of Hematology/Oncology, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada.
Abstract
OBJECTIVES: This study explored how signs and symptoms of pyruvate kinase (PK) deficiency, a rare hemolytic anemia caused by mutations in the PKLR gene, impacts patients' health-related quality of life (HRQoL). METHODS: Interviews with 21 adults with PK deficiency in the United States, Netherlands, and Germany were conducted. Participants were asked to describe signs, symptoms, and impacts of the disease on their daily lives. Interviews were transcribed and analyzed using qualitative analysis methods. RESULTS: The most common signs and symptoms reported were yellow eyes (n = 19), tiredness (n = 18), yellow skin (n = 17), fatigue (n = 15), low energy (n = 13), and shortness of breath (n = 13). Furthermore, signs and symptoms of PK deficiency negatively impact the ability to perform physical activities, appearance, social activities, emotional states, activities of daily living, leisure activities, work and/or school, sleep, and cognitive states of those living with PK deficiency. A conceptual model is presented that further demonstrates the profound impact that signs and symptoms of PK deficiency have on dimensions of patients' HRQoL. CONCLUSIONS: This is the first study that provides patient perspective on the burden of living with PK deficiency and lays the foundation for future studies to examine the effect of pharmacologic interventions on overall HRQoL for patients living with PK deficiency.
OBJECTIVES: This study explored how signs and symptoms of pyruvate kinase (PK) deficiency, a rare hemolytic anemia caused by mutations in the PKLR gene, impacts patients' health-related quality of life (HRQoL). METHODS: Interviews with 21 adults with PK deficiency in the United States, Netherlands, and Germany were conducted. Participants were asked to describe signs, symptoms, and impacts of the disease on their daily lives. Interviews were transcribed and analyzed using qualitative analysis methods. RESULTS: The most common signs and symptoms reported were yellow eyes (n = 19), tiredness (n = 18), yellow skin (n = 17), fatigue (n = 15), low energy (n = 13), and shortness of breath (n = 13). Furthermore, signs and symptoms of PK deficiency negatively impact the ability to perform physical activities, appearance, social activities, emotional states, activities of daily living, leisure activities, work and/or school, sleep, and cognitive states of those living with PK deficiency. A conceptual model is presented that further demonstrates the profound impact that signs and symptoms of PK deficiency have on dimensions of patients' HRQoL. CONCLUSIONS: This is the first study that provides patient perspective on the burden of living with PK deficiency and lays the foundation for future studies to examine the effect of pharmacologic interventions on overall HRQoL for patients living with PK deficiency.
Authors: Paola Bianchi; Elisa Fermo; Kimberly Lezon-Geyda; Eduard J van Beers; Holmes D Morton; Wilma Barcellini; Bertil Glader; Satheesh Chonat; Yaddanapudi Ravindranath; Peter E Newburger; Nina Kollmar; Jenny M Despotovic; Madeleine Verhovsek; Mukta Sharma; Janet L Kwiatkowski; Kevin H M Kuo; Marcin W Wlodarski; Hassan M Yaish; Susanne Holzhauer; Heng Wang; Joachim Kunz; Kathryn Addonizio; Hasan Al-Sayegh; Wendy B London; Oliver Andres; Richard van Wijk; Patrick G Gallagher; Rachael F F Grace Journal: Am J Hematol Date: 2020-03-06 Impact factor: 10.047
Authors: Audra N Boscoe; Yan Yan; Elizabeth Hedgeman; Eduard J van Beers; Hanny Al-Samkari; Wilma Barcellini; Stefan W Eber; Bertil Glader; Hassan M Yaish; Satheesh Chonat; Mukta Sharma; Kevin H M Kuo; Ellis J Neufeld; Heng Wang; Madeleine Verhovsek; Sujit Sheth; Rachael F Grace Journal: Eur J Haematol Date: 2021-01-24 Impact factor: 2.997
Authors: Bruno Fattizzo; Francesca Cavallaro; Anna Paola Maria Luisa Marcello; Cristina Vercellati; Wilma Barcellini Journal: J Blood Med Date: 2022-09-01
Authors: Sam Salek; Audra N Boscoe; Sarah Piantedosi; Shayna Egan; Christopher J Evans; Ted Wells; Jennifer Cohen; Robert J Klaassen; Rachael Grace; Michael Storm Journal: Eur J Haematol Date: 2020-02-24 Impact factor: 2.997
Authors: Hanny Al-Samkari; Eduard J Van Beers; Kevin H M Kuo; Wilma Barcellini; Paola Bianchi; Andreas Glenthøj; María Del Mar Mañú Pereira; Richard Van Wijk; Bertil Glader; Rachael F Grace Journal: Haematologica Date: 2020-09-01 Impact factor: 9.941
Authors: Hanny Al-Samkari; Eduard J van Beers; D Holmes Morton; Stefan W Eber; Satheesh Chonat; Kevin H M Kuo; Nina Kollmar; Heng Wang; Vicky R Breakey; Sujit Sheth; Mukta Sharma; Peter W Forbes; Robert J Klaassen; Rachael F Grace Journal: Blood Adv Date: 2022-03-22